schliessen

Filtern

 

Bibliotheken

Regulation of gastric nesfatin-1/NUCB2

Originally identified in the hypothalamus as a satiety factor, recent studies provide evidence that nefatin-1/NUCB2 is a gutbrain peptide with a broader array of actions. Detection of abundant nesfatin-1/NUCB2 in gastric X/A like endocrine cells, which also produce the orexigenic hormone ghrelin, in... Full description

Journal Title: Current pharmaceutical design 2013, Vol.19(39), pp.6981-5
Main Author: Li, Ziru
Other Authors: Mulholland, Michael , Zhang, Weizhen
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1873-4286 ; PMID: 23537086 Version:1
Link: http://pubmed.gov/23537086
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline23537086
title: Regulation of gastric nesfatin-1/NUCB2
format: Article
creator:
  • Li, Ziru
  • Mulholland, Michael
  • Zhang, Weizhen
subjects:
  • Calcium-Binding Proteins -- Physiology
  • DNA-Binding Proteins -- Physiology
  • Nerve Tissue Proteins -- Physiology
  • Stomach -- Physiology
ispartof: Current pharmaceutical design, 2013, Vol.19(39), pp.6981-5
description: Originally identified in the hypothalamus as a satiety factor, recent studies provide evidence that nefatin-1/NUCB2 is a gutbrain peptide with a broader array of actions. Detection of abundant nesfatin-1/NUCB2 in gastric X/A like endocrine cells, which also produce the orexigenic hormone ghrelin, indicates that gastric mucosa may be one of the predominant sources of nesfatin-1/NUCB2. Functional studies have revealed significant effects of nefatin-1 on inhibition of feeding behavior and on glucose homeostasis. These metabolic functions make nesfatin-1/NUCB2 a novel candidate for treatment of obesity and diabetes. However, deficiencies in our understanding of nesfatin-1/NUCB2 receptor pose a significant hurdle for therapies that target its action. Defining novel pathways to alter the production of nesfatin-1/NUCB2 would shift therapeutic focus to gastric targets. A necessary precondition is improved understanding of the mechanisms by which nesfatin-1/NUCB2 is synthesized and secreted by gastric...
language: eng
source:
identifier: E-ISSN: 1873-4286 ; PMID: 23537086 Version:1
fulltext: fulltext
issn:
  • 18734286
  • 1873-4286
url: Link


@attributes
ID1708465839
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid23537086
sourceidmedline
recordidTN_medline23537086
sourceformatXML
sourcesystemPC
pqid1462762811
ingidben/cpd/2013/00000019/00000039/art00023
display
typearticle
titleRegulation of gastric nesfatin-1/NUCB2
creatorLi, Ziru ; Mulholland, Michael ; Zhang, Weizhen
ispartofCurrent pharmaceutical design, 2013, Vol.19(39), pp.6981-5
identifierE-ISSN: 1873-4286 ; PMID: 23537086 Version:1
subjectCalcium-Binding Proteins -- Physiology ; DNA-Binding Proteins -- Physiology ; Nerve Tissue Proteins -- Physiology ; Stomach -- Physiology
descriptionOriginally identified in the hypothalamus as a satiety factor, recent studies provide evidence that nefatin-1/NUCB2 is a gutbrain peptide with a broader array of actions. Detection of abundant nesfatin-1/NUCB2 in gastric X/A like endocrine cells, which also produce the orexigenic hormone ghrelin, indicates that gastric mucosa may be one of the predominant sources of nesfatin-1/NUCB2. Functional studies have revealed significant effects of nefatin-1 on inhibition of feeding behavior and on glucose homeostasis. These metabolic functions make nesfatin-1/NUCB2 a novel candidate for treatment of obesity and diabetes. However, deficiencies in our understanding of nesfatin-1/NUCB2 receptor pose a significant hurdle for therapies that target its action. Defining novel pathways to alter the production of nesfatin-1/NUCB2 would shift therapeutic focus to gastric targets. A necessary precondition is improved understanding of the mechanisms by which nesfatin-1/NUCB2 is synthesized and secreted by gastric...
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/23537086$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Li, Ziru
1Mulholland, Michael
2Zhang, Weizhen
titleRegulation of gastric nesfatin-1/NUCB2
descriptionOriginally identified in the hypothalamus as a satiety factor, recent studies provide evidence that nefatin-1/NUCB2 is a gutbrain peptide with a broader array of actions. Detection of abundant nesfatin-1/NUCB2 in gastric X/A like endocrine cells, which also produce the orexigenic hormone ghrelin, indicates that gastric mucosa may be one of the predominant sources of nesfatin-1/NUCB2. Functional studies have revealed significant effects of nefatin-1 on inhibition of feeding behavior and on glucose homeostasis. These metabolic functions make nesfatin-1/NUCB2 a novel candidate for treatment of obesity and diabetes. However, deficiencies in our understanding of nesfatin-1/NUCB2 receptor pose a significant hurdle for therapies that target its action. Defining novel pathways to alter the production of nesfatin-1/NUCB2 would shift therapeutic focus to gastric targets. A necessary precondition is improved understanding of the mechanisms by which nesfatin-1/NUCB2 is synthesized and secreted by gastric...
subject
0Calcium-Binding Proteins -- Physiology
1DNA-Binding Proteins -- Physiology
2Nerve Tissue Proteins -- Physiology
3Stomach -- Physiology
general
023537086
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
3MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline23537086
issn
018734286
11873-4286
rsrctypearticle
creationdate2013
addtitleCurrent pharmaceutical design
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr412013
citationpf 6981 vol 19 issue 39
startdate20130101
enddate20131231
lsr30VSR-Enriched:[pages, ingid, pqid, doi]
sort
titleRegulation of gastric nesfatin-1/NUCB2
authorLi, Ziru ; Mulholland, Michael ; Zhang, Weizhen
creationdate20130000
lso0120130000
facets
frbrgroupid8526818704265010530
frbrtype5
newrecords20190701
languageeng
creationdate2013
topic
0Calcium-Binding Proteins–Physiology
1DNA-Binding Proteins–Physiology
2Nerve Tissue Proteins–Physiology
3Stomach–Physiology
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Li, Ziru
1Mulholland, Michael
2Zhang, Weizhen
jtitleCurrent Pharmaceutical Design
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Li
1Mulholland
2Zhang
aufirst
0Ziru
1Michael
2Weizhen
au
0Li, Ziru
1Mulholland, Michael
2Zhang, Weizhen
atitleRegulation of gastric nesfatin-1/NUCB2
jtitleCurrent pharmaceutical design
date2013
risdate2013
volume19
issue39
spage6981
pages6981-6985
issn1381-6128
eissn1873-4286
formatjournal
genrearticle
ristypeJOUR
abstractOriginally identified in the hypothalamus as a satiety factor, recent studies provide evidence that nefatin-1/NUCB2 is a gutbrain peptide with a broader array of actions. Detection of abundant nesfatin-1/NUCB2 in gastric X/A like endocrine cells, which also produce the orexigenic hormone ghrelin, indicates that gastric mucosa may be one of the predominant sources of nesfatin-1/NUCB2. Functional studies have revealed significant effects of nefatin-1 on inhibition of feeding behavior and on glucose homeostasis. These metabolic functions make nesfatin-1/NUCB2 a novel candidate for treatment of obesity and diabetes. However, deficiencies in our understanding of nesfatin-1/NUCB2 receptor pose a significant hurdle for therapies that target its action. Defining novel pathways to alter the production of nesfatin-1/NUCB2 would shift therapeutic focus to gastric targets. A necessary precondition is improved understanding of the mechanisms by which nesfatin-1/NUCB2 is synthesized and secreted by gastric...
pmid23537086
doi10.2174/138161281939131127143306